Diagenode
Hologic Reports Gains in Non-COVID Diagnostics, Surgical Products
Company beats its Q3 earnings guidance on strength of women's health diagnostics income, and CEO Steve MacMillan predicted relief from chip supply problems
Hologic Preliminary Fiscal Q1 Revenues Drop 9 Percent
The firm expects fiscal Q1 Diagnostics revenues of $950.4 million, down 16 percent compared to the prior-year quarter when its COVID-19 revenues surged.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
Diagenode already sells more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses for multiple infectious diseases.
Aug 17, 2018
Diagenode Acquires Epigenetics Firm Nxt-Dx
Jun 27, 2013
Apr 18, 2013
Nov 8, 2012
Aug 16, 2011
Mar 8, 2011
Mar 16, 2010